Prospective Multicentre Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
Phase of Trial: Phase IV
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms IVENT
- Sponsors Bayer
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.
- 12 Feb 2018 Planned End Date changed from 7 Feb 2018 to 28 Feb 2018.
- 12 Jan 2018 Planned End Date changed from 30 Nov 2017 to 7 Feb 2018.